Submit to Life Review for Life Propose a Special Issue

Journal Browser

► Journal Browser

Advance in Clinical Radiotherapy: Translational and Prognostic Factors

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (22 March 2022) | Viewed by 6835

Share This Special Issue

Special Issue Editor

Dr. Eng-Yen Huang

E-Mail Website
Guest Editor

Professor, Department of Radiation Oncology, Proton and Radiation Therapy Center, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, No.129, Dapi Rd., Niaosong Dist., Kaohsiung, Taiwan
Interests: precision radiotherapy; proton beam therapy; glycobiology; radiation-induced toxicity; translational research

Special Issue Information

Dear Colleagues,

Radiotherapy has progressed toward personalization. In addition to improving accuracy using advanced technology, it is also very important to identify patients with a high risk of recurrence. These patients need more aggressive treatments such as chemotherapy, target therapy, and immunotherapy. This relies on the use of clinical information such as the data available from images, signal records, and blood sampling including tumor markers, cell-free DNA, and circulating tumor cells. Additionally, pathological information from immunohistochemistry (IHC) and genetic alteration is useful for the evaluation of prognosis. The high and low levels of these biomarkers can be used to classify patients at risk of recurrence for the basis of future clinical trials to changes in radiation dose escalation/de-escalation or treatment volume. This Special Issue will focus on the clinical treatment effects of the above concepts. In addition, various precise treatments such as particle therapy and stereotactic body radiotherapy (SBRT) and comparison of the effects of different radiation doses/volumes are welcome in terms of treatment technology. Original and review articles are welcome to enrich the literature and the scientific community.

Dr. Eng-Yen Huang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

radiotherapy
tumor marker
cell-free DNA
circulating tumor cells
biomarker
prognostic factor
translational factor
particles therapy
stereotactic body radiotherapy
treatment outcome

Published Papers (3 papers)

Download All Papers

Research

Jump to: Other

10 pages, 673 KiB

Open AccessArticle

The Impact of Weight Loss during Chemoradiotherapy for Unresectable Esophageal Cancer: Real-World Results

by Tzu-Ting Huang, Shang-Yu Chou, Yun-Hsuan Lin, Shau-Hsuan Li, Yen-Hao Chen, Hung-I Lu, Chien-Ming Lo, Fu-Min Fang, Yi-Chun Chiu, Yeh-Pin Chou and Yu-Ming Wang

Life 2022, 12(5), 706; https://doi.org/10.3390/life12050706 - 08 May 2022

Cited by 3 | Viewed by 1553

Abstract

Weight loss is a common phenomenon presented in unresectable esophageal cancer (EC) patients during their definitive chemoradiotherapy (dCRT) treatment course. This study explored the prognostic value of weight changes during dCRT in unresectable EC patients. From 2009 to 2017, 69 cT4b thoracic EC patients undergoing complete curative dCRT without baseline malnutrition were included. Clinical factors were analyzed via the Cox proportional hazards model and survival was analyzed by the Kaplan–Meier method. During dCRT, the median weight loss percentage was 5.51% (IQR = 2.77–8.85%), and the lowest body weight was reached at 35 days (IQR = 23–43 days). Median OS of these patients was 13.5 months. Both univariate and multivariate analysis demonstrated that weight loss ≤ 4% during dCRT was significantly associated with superior OS with a hazard ratio of 2.61 (95% CI: 1.40–4.85, p = 0.002). The median OS for patients with weight loss ≤ 4% and >4% during dCRT was 59.6 months and 9.7 months, respectively (p = 0.001). Our study demonstrated that weight loss ≤ 4% during dCRT course is a favorable prognostic factor for cT4b EC patients. This index could serve as a nutrition support reference for unresectable EC patients receiving dCRT in the future. Full article

(This article belongs to the Special Issue Advance in Clinical Radiotherapy: Translational and Prognostic Factors)

► Show Figures

Figure 1

11 pages, 1122 KiB

Open AccessArticle

Feasibility and Safety of Intraoperative Radiotherapy with Low Energy X-ray Photon Therapy for Recurrent Gynecological Cancer: A Case Series

by Hui-Hua Chen, Pei-Yu Hou, Wan-Hua Ting, Pei-Wei Shueng and Sheng-Mou Hsiao

Life 2022, 12(5), 685; https://doi.org/10.3390/life12050685 - 05 May 2022

Viewed by 1729

Abstract

Objectives: To evaluate the feasibility and safety of low energy X-ray photon intraoperative radiotherapy (IORT) as an adjuvant therapy for recurrent gynecological cancer.Methods: Medical records of all recurrence gynecological cancer patients who underwent IORT were reviewed. Results: Between January 2018 and December 2021, five women (including cervical cancer (n = 2), endometrial cancer (n = 2), and uterine leiomyosarcoma (n = 1)), who underwent IORT and surgical resection for recurrent gynecologic cancer were reviewed. A median dose of 15.62 Gy (range, 12 to 20 Gy) was used for IORT. Repeated IORT and surgical resection was performed in two women. Three women experienced local recurrence, and three women died during follow-up. The 1-year local control rate was 60%. The 2-year overall survival rate was 30%. There was no Clavien–Dindo classification grade III–V complication. Conclusion: IORT using low energy X-ray photon therapy seems to be feasible and safe as an adjuvant therapy in women who underwent salvage surgery for recurrent gynecologic cancer. However, large-scale prospective studies are needed to confirm our findings and evaluate its efficacy. Full article

(This article belongs to the Special Issue Advance in Clinical Radiotherapy: Translational and Prognostic Factors)

► Show Figures

Figure 1

Other

Jump to: Research

13 pages, 1993 KiB

Open AccessCase Report

Compassionate Treatment of Brainstem Tumors with Boron Neutron Capture Therapy: A Case Series

by Yi-Wei Chen, Yi-Yen Lee, Chun-Fu Lin, Ting-Yu Huang, Shih-Hung Ke, Pei-Fan Mu, Po-Shen Pan, Jen-Kun Chen, Tien-Li Lan, Ping-Chuan Hsu, Muh-Lii Liang, Hsin-Hung Chen, Feng-Chi Chang, Chih-Chun Wu, Shih-Chieh Lin, Jia-Cheng Lee, Shih-Kuan Chen, Hong-Ming Liu, Jinn-Jer Peir, Hui-Yu Tsai, Ko-Han Lin, Nan-Jing Peng, Kuan-Hsuan Chen, Yuan-Hung Wu, Yu-Mei Kang, Wan-Chin Yang, Shueh-Chun Liou, Wei-Hsuan Huang, Hiroki Tanaka, Tai-Tong Wong, Yee Chao and Fong-In Chou Show full author list Hide full author list

Life 2022, 12(4), 566; https://doi.org/10.3390/life12040566 - 10 Apr 2022

Cited by 6 | Viewed by 3041

Abstract

Brainstem tumors are heterogenous and cancerous glioma tumors arising from the midbrain, pons, and the medulla that are relatively common in children, accounting for 10% to 20% of all pediatric brain tumors. However, the prognosis of aggressive brainstem gliomas remains extremely poor despite aggressive treatment with chemotherapy and radiotherapy. That means there are many life-threatening patients who have exhausted all available treatment options and are beginning to face end-of-life stage. Therefore, the unique properties of highly selective heavy particle irradiation with boron neutron capture therapy (BNCT) may be well suited to prolong the lives of patients with end-stage brainstem gliomas. Herein, we report a case series of life-threatening patients with end-stage brainstem glioma who eligible for Emergency and Compassionate Use, in whom we performed a scheduled two fractions of salvage BNCT strategy with low treatment dosage each time. No patients experienced acute or late adverse events related to BNCT. There were 3 patients who relapsed after two fractionated BNCT treatment, characterized by younger age, lower T/N ratio, and receiving lower treatment dose. Therefore, two fractionated low-dose BNCT may be a promising treatment for end-stage brainstem tumors. For younger patients with low T/N ratios, more fractionated low-dose BNCT should be considered. Full article

(This article belongs to the Special Issue Advance in Clinical Radiotherapy: Translational and Prognostic Factors)

► Show Figures